WO2011040070A1 - 紫外線障害軽減経口組成物 - Google Patents
紫外線障害軽減経口組成物 Download PDFInfo
- Publication number
- WO2011040070A1 WO2011040070A1 PCT/JP2010/055841 JP2010055841W WO2011040070A1 WO 2011040070 A1 WO2011040070 A1 WO 2011040070A1 JP 2010055841 W JP2010055841 W JP 2010055841W WO 2011040070 A1 WO2011040070 A1 WO 2011040070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methionine
- composition
- composition according
- irradiation
- skin diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000006378 damage Effects 0.000 title claims abstract description 35
- 230000005855 radiation Effects 0.000 title abstract description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 94
- 229930182817 methionine Natural products 0.000 claims abstract description 87
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000002177 Cataract Diseases 0.000 claims abstract description 23
- 208000017520 skin disease Diseases 0.000 claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 230000037303 wrinkles Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 9
- 230000036211 photosensitivity Effects 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 206010015150 Erythema Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 206010072578 Chronic actinic dermatitis Diseases 0.000 claims description 5
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 5
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000002440 photoallergic dermatitis Diseases 0.000 claims description 5
- 208000017983 photosensitivity disease Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 208000013165 Bowen disease Diseases 0.000 claims description 4
- 208000019337 Bowen disease of the skin Diseases 0.000 claims description 4
- 208000002506 Darier Disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000019872 Drug Eruptions Diseases 0.000 claims description 4
- 208000012777 Hartnup Disease Diseases 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 206010023369 Keratosis follicular Diseases 0.000 claims description 4
- 206010029400 Nicotinic acid deficiency Diseases 0.000 claims description 4
- 241000287127 Passeridae Species 0.000 claims description 4
- 208000002141 Pellagra Diseases 0.000 claims description 4
- 206010051246 Photodermatosis Diseases 0.000 claims description 4
- 241000097929 Porphyria Species 0.000 claims description 4
- 208000010642 Porphyrias Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 201000004607 keratosis follicularis Diseases 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 230000001153 anti-wrinkle effect Effects 0.000 abstract 2
- 229960004452 methionine Drugs 0.000 description 89
- 235000006109 methionine Nutrition 0.000 description 83
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 42
- 229930182818 D-methionine Natural products 0.000 description 39
- 235000002639 sodium chloride Nutrition 0.000 description 36
- 238000009472 formulation Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 206010040954 Skin wrinkling Diseases 0.000 description 16
- 238000002156 mixing Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 10
- -1 2-ethylhexyl paramethoxycinnamate Chemical compound 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000013557 nattō Nutrition 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 235000013555 soy sauce Nutrition 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000037373 wrinkle formation Effects 0.000 description 8
- 150000008575 L-amino acids Chemical class 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 150000008574 D-amino acids Chemical class 0.000 description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 6
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 6
- 229930195722 L-methionine Natural products 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 235000013618 yogurt Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 240000008415 Lactuca sativa Species 0.000 description 4
- 244000294411 Mirabilis expansa Species 0.000 description 4
- 235000015429 Mirabilis expansa Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000006002 Pepper Substances 0.000 description 4
- 235000016761 Piper aduncum Nutrition 0.000 description 4
- 240000003889 Piper guineense Species 0.000 description 4
- 235000017804 Piper guineense Nutrition 0.000 description 4
- 235000008184 Piper nigrum Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000014510 cooky Nutrition 0.000 description 4
- 235000013536 miso Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 235000012045 salad Nutrition 0.000 description 4
- 206010008570 Chloasma Diseases 0.000 description 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 3
- 229930182820 D-proline Natural products 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 208000002352 blister Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 3
- 239000008268 mayonnaise Substances 0.000 description 3
- 235000010746 mayonnaise Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 201000008525 senile cataract Diseases 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940008396 carrot extract Drugs 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002741 methionine derivatives Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000024351 regulation of hormone secretion Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/245—Amino acids, nucleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention relates to an ultraviolet ray-damaging oral composition
- an ultraviolet ray-damaging oral composition comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof, methionine and derivatives and / or salts thereof.
- a method for improving skin diseases and cosmetic conditions by exposure to ultraviolet radiation comprising the step of administering one or more compounds selected from the group consisting of: and treating cataract comprising the step of administering said compounds and / or And how to prevent.
- UV-A long-wavelength ultraviolet rays
- UV-B medium-wavelength ultraviolet rays
- UV-C short-wavelength ultraviolet rays
- Non-Patent Document 1 diseases involving ultraviolet rays include wrinkles, erythema, xeroderma pigmentosum, chronic actinic dermatitis, squamous cell carcinoma, basal cell carcinoma, malignant melanoma, Bowen's disease, actinic keratosis
- photosensitivity, varicella-like blistering disease and photocontact dermatitis are sun dermatitis, chronic photodermatosis, photokeratosis, photolabiitis, Favre-Racochot disease, photosensitivity, Photo contact dermatitis, belllock dermatitis, photosensitivity drug eruption, polymorphic sun rash, vaginal vesicular vesicle, sun urticaria, chronic photosensitivity dermatitis, xeroderma pigmentosum, sparrow egg spot, porphyria, Pellagra, Hartnup's disease, actinic keratosis, dermatomyositis, lichen planus
- ultraviolet ray scattering agents such as titanium oxide that inhibit skin absorption of ultraviolet rays
- ultraviolet absorbers such as 2-ethylhexyl paramethoxycinnamate
- Antioxidants that remove free radicals are known.
- UV scattering agents and UV absorbers are effective for sunscreen outdoors, they are not used on a daily basis. Antioxidants also have problems with stability and safety.
- only symptomatic treatments are known as therapeutic agents for skin damage caused by ultraviolet rays. In addition, it is difficult to administer continuously with a skin external preparation.
- the present invention provides an oral composition for alleviating UV damage, comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof.
- the methionine may be D-form.
- the UV damage reducing oral composition may be a wrinkle inhibitor.
- the oral composition for reducing UV damage may be used as a pharmaceutical for skin diseases.
- the skin diseases include erythema, sun dermatitis, chronic photodermatosis, photokeratosis, photolabiitis, Favre-Racochot disease, photosensitivity, photocontact dermatitis, belllock dermatitis, photosensitivity drug eruption, Polymorphic solar eruption, varicella-like blistering, sun urticaria, chronic photosensitivity dermatitis, xeroderma pigmentosum, sparrow egg spot, porphyria, pellagra, Hartnup disease, actinic keratosis, dermatomyositis, lichen planus May be selected from the group consisting of: Darier's disease, pore erythema, rosacea, atopic dermatitis, melasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and Bowen's disease.
- the drug for skin diseases may be a therapeutic agent for skin diseases.
- the drug for skin diseases may be a prophylactic agent for skin diseases.
- the UV damage reducing oral composition of the present invention may be used as food.
- the UV damage reducing oral composition of the present invention may be used as a pharmaceutical for cataracts.
- the medicinal product for cataract may be a therapeutic agent for cataract or a preventive agent for cataract.
- the cataract may be senile cataract.
- the present invention relates to a skin disease caused by UV exposure, comprising the step of administering an oral composition for reducing UV damage, comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof.
- an oral composition for reducing UV damage comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof.
- the skin diseases include erythema, sun dermatitis, chronic photodermatosis, photokeratosis, photolabiitis, Favre-Racochot disease, photosensitivity, photocontact dermatitis, belllock dermatitis, photosensitivity drug eruption, Polymorphic solar eruption, varicella-like blistering, sun urticaria, chronic photosensitivity dermatitis, xeroderma pigmentosum, sparrow egg spot, porphyria, pellagra, Hartnup disease, actinic keratosis, dermatomyositis, lichen planus May be selected from the group consisting of: Darier's disease, pore erythema, rosacea, atopic dermatitis, melasma, herpes simplex, lupus erythematosus, squamous cell carcinoma, basal cell carcinoma and Bowen's disease.
- the methionine may be D-form.
- the present invention relates to a skin cosmetic condition comprising the step of administering an oral composition for reducing UV damage comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof.
- an oral composition for reducing UV damage comprising one or more compounds selected from the group consisting of methionine and derivatives and / or salts thereof.
- the oral composition for reducing UV damage comprising one or more compounds selected from the group consisting of the methionine and derivatives and / or salts thereof is a food composition.
- the methionine may be D-form.
- the improvement of the cosmetic condition of the skin may be wrinkle suppression, but is not limited thereto.
- the present invention treats cataracts and comprises a step of administering a composition comprising one or more compounds selected from the group consisting of L- and D-methionine and derivatives and / or salts thereof.
- a method of preventing is provided.
- the cataract may be senile cataract.
- the “salt” of methionine means any salt including a metal salt, an amine salt and the like, provided that the effect of reducing UV damage of methionine is not impaired.
- the metal salt may include an alkali metal salt, an alkaline earth metal salt, and the like.
- the amine salt may include a triethylamine salt, a benzylamine salt, or the like.
- the term “derivative” of methionine means that any methionine molecule is an amino group, a carboxyl group, or a side chain, and any atomic group, provided that it does not impair the effect of reducing methionine's UV damage. Refers to a covalent bond.
- Any of the atomic groups includes a protecting group such as an N-phenylacetyl group or a 4,4′-dimethoxytrityl (DMT) group, and a biopolymer such as a protein, peptide, sugar, lipid, nucleic acid, or the like.
- Synthetic polymers such as polystyrene, polyethylene, polyvinyl, and polyester, and functional groups such as ester groups, but are not limited thereto.
- the ester group may include, for example, methyl ester, ethyl ester, other aliphatic esters, or aromatic esters.
- Amino acids have L-isomers and D-isomers as optical isomers, but natural proteins are L-amino acids with peptide bonds, and only L-amino acids are used with the exception of bacterial cell walls. Therefore, it has been considered that mammals including humans have only L-amino acids and use only L-amino acids.
- D-amino acids are used as a starting material for antibiotics produced by bacteria, and when L-amino acids and D-amino acid mixtures obtained in equal amounts when amino acids are chemically synthesized are L-
- L-amino acids and D-amino acid mixtures obtained in equal amounts when amino acids are chemically synthesized are L-
- a food additive in which D-amino acid is used as it is as a DL-amino acid mixture in order to save the cost of fractionating only amino acids.
- only a D-amino acid containing no L-amino acid is industrially used as a physiologically active substance.
- D-Serine and D-aspartic acid are relatively researched because of the high proportion of D-form.
- D-serine is localized in the cerebrum and hippocampus and has been clarified as a regulator of NMDA receptors in the brain.
- D-aspartic acid is found to be localized in the testis and pineal gland and has been shown to be involved in the regulation of hormone secretion (Japanese Patent Laid-Open No. 2005-3558).
- the physiological effects of L- and D-methionine on the skin, especially UV damage have not been clarified.
- the ultraviolet damage reducing oral composition containing L- and / or D-methionine of the present invention is a novel invention.
- the methionine of the present invention has the effect of reducing UV damage at a concentration of 0.001 to 100 ⁇ M for cultured human fibroblasts or 10 mM for mice, as shown in the following examples. Therefore, the amount of methionine contained in the pharmaceutical composition of the present invention, the wrinkle suppressant and the food composition can be any content, provided that methionine in this concentration range is delivered to fibroblasts in living skin tissue. It doesn't matter how much. When the composition of the present invention is an internal preparation, the content of methionine may be in the range of 0.000001% to 100% by weight.
- the content of methionine is preferably 0.000002% by weight to 80% by weight, and most preferably 0.00002% by weight to 60% by weight.
- the lower limit of the daily intake of D-methionine contained in the composition of the present invention may be 0.01 ng per kg body weight, preferably 0.1 ng, more preferably 1 ng.
- the lower limit of the daily intake of L-methionine contained in the composition of the present invention is less than the clinical drug dose (2 mg or more per kg body weight) and may be 0.01 mg per kg body weight, 0.1 mg is preferable and 1 mg is more preferable.
- the pharmaceutical composition of the present invention in addition to a methionine simple substance, a methionine salt and / or a derivative capable of releasing methionine by a drug metabolizing enzyme or the like in vivo, is provided that it does not impair the effect of reducing the UV damage of methionine. It may further contain one or more pharmaceutically acceptable additives.
- the additives include diluents and swelling agents, binders and adhesives, lubricants, glidants, plasticizers, disintegrants, carrier solvents, buffering agents, colorants, fragrances, Includes, but is not limited to, sweeteners, preservatives and stabilizers, adsorbents, and other pharmaceutical additives known to those skilled in the art.
- the wrinkle inhibitor of the present invention can be prepared using only methionine, a salt of methionine and / or a derivative capable of releasing methionine in vivo by a drug metabolizing enzyme or the like as an active ingredient.
- other components used for external preparations for skin such as cosmetics and pharmaceuticals including quasi drugs can be appropriately blended as necessary.
- the other components include oils, surfactants, powders, coloring materials, water, alcohols, thickeners, chelating agents, silicones, antioxidants, ultraviolet absorbers, and humectants. , Fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers and the like.
- the food composition of the present invention is a seasoning on the condition that methionine, a salt of methionine and / or a derivative capable of releasing methionine by a drug metabolizing enzyme or the like in vivo, does not impair the effect of reducing UV damage of methionine. , Coloring agents, preservatives and other food acceptable ingredients.
- the food composition of the present invention may be any conventional food composition such as soft drinks, gummi, candy, and tablet confectionery, and is not limited to the above examples.
- UV exposure is considered to be one of the causes of eye diseases, particularly cataracts, as well as skin diseases.
- mice it is known that long-term exposure to UV rays causes white turbidity in the anterior cortex of the lens, which can be used to experimentally create a cataract model (Takami Maezato and Shuzo Iwata, “The lens's biochemical mechanism. 318-323, edited by Shuzo Iwata, Medical Sakai Publishing, Tokyo (1986)).
- Ultraviolet ray damage test using cultured cells Method of ultraviolet irradiation and methionine addition
- Commercially available human neonatal dermal fibroblasts (Cryo NHDF-Neo, Sanko Junyaku) were used.
- the cells are seeded in a commercially available 35 mm diameter culture dish (BD FALCON 353001, Nippon Becton Dickinson) so as to be 2 ⁇ 10 5 cells / mL, and a commercially available cell culture medium (D-MEM (1 g / L glucose), Wako Pure Chemical Industries, Ltd.) was cultured in a medium (hereinafter referred to as “normal medium”) supplemented with 10% fetal bovine serum and 1% antibiotics (15240-062, GIBCO). The cells were cultured for about 24 hours at 37 ° C., 5% CO 2 and saturated water vapor atmosphere.
- the medium in which the cells are cultured is switched to 1 mL of BSO medium supplemented with 1 ⁇ 10 ⁇ 3 % of BSO (L-Buthionine- (S, R) -sulfoximine, Wako Pure Chemicals), which is a biosynthesis inhibitor of glutathione.
- BSO L-Buthionine- (S, R) -sulfoximine, Wako Pure Chemicals
- Incubation was performed at 37 ° C., 5% CO 2 and saturated steam atmosphere for about 24 hours.
- the BSO medium was prepared by diluting a stock solution for storage in which 0.2% BSO was dissolved in ethyl alcohol 200 times in the normal medium.
- addition before irradiation When examining the effect of adding methionine before UV irradiation (hereinafter referred to as “addition before irradiation”), 0.001 to 100 ⁇ M L- or D-methionine is added 24 hours before irradiation. It switched to the added BSO culture medium. Ultraviolet irradiation after switching to a medium supplemented with 0.1 ⁇ M D-proline was used as a positive control, and ultraviolet irradiation in a medium without these amino acids was used as a negative control.
- Ultraviolet irradiation medium Iron chloride (II) is dissolved in distilled water so as to be 2 ⁇ 10 ⁇ 3 %, and the dissolved solution is diluted 200 times (final concentration 1 ⁇ 10 ⁇ 5 %) with calcium ions, A medium prepared by diluting with phosphate buffered saline PBS (+) containing magnesium ions (hereinafter referred to as “ultraviolet irradiation medium”) was preheated to 37 ° C. and used.
- UV-A irradiation Before the UV-A irradiation, the medium was replaced with 1 mL of the ultraviolet irradiation medium.
- the UV-A irradiation is performed by using an ultraviolet light uniform exposure apparatus UVE-502S + EL-160 (Minami Electric Mfg. Co., Ltd.) and removing ultraviolet rays of 320 nm to 400 nm from about 20 cm above the culture dish with the lid of the culture dish removed. It was carried out with 9 J / cm 2 irradiation. The amount of ultraviolet rays was measured using UV RADIOMETER UVR-3036 / S (Topcon Co., Ltd.).
- addition after irradiation 0.001 to 100 ⁇ M L- or D-methionine was added to the culture medium for 40 hours.
- alamarBlue (trademark, Invitrogen) was added to the medium to a final concentration of 10%, and 3 hours later, Ahmed S. et al. A. (J. Immunol. Method. 170, 211-224 (1994)) and the manufacturer's instructions, the fluorescence intensity of the supernatant was measured at an excitation wavelength of 544 nm and a fluorescence wavelength of 590 nm.
- FIG. 1 shows the experimental results of examining the effects of pre-irradiation addition of L- or D-methionine on fibroblast damage caused by UV-A 9 J / cm 2 UV irradiation.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated four times under the same condition.
- asterisk (*) indicates that p is less than 5%
- asterisk (**) indicates that p is less than 1%
- asterisk (***) indicates that p is less than 0.1%.
- the percentage of viable cells when pre-irradiated with 0.001 ⁇ M, 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M or 100 ⁇ M L-methionine is 40%, 72%, 67%, 45%, 73% or 62, respectively. %Met. From the above results, the addition of L- or D-methionine increased the viable cell rate and reduced cell death.
- FIG. 2 shows the experimental results of examining the effects of post-irradiation addition of D-methionine on fibroblast damage caused by UV-A 8 J / cm 2 UV irradiation.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated four times under the same condition.
- An asterisk (***) indicates that p is less than 0.1% by Bonferroni / Dunn test.
- UV-B light source; Toshiba FL-20 SE fluorescent lamp manufactured by Toshiba Electric
- the total irradiation dose was 4.482 J / cm 2 .
- the amount of ultraviolet rays used was a value measured with UVRADIOMETER (UVR-305 / 365D (II), Topcon).
- UV-B irradiation period 10 mM D-methionine was administered in a water bottle. As a control, drinking water was administered in the same manner. The water bottle was changed once a week.
- FIG. 3 shows the results of an experiment examining the effect of D-methionine on skin thickening caused by UV-B irradiation with a total irradiation dose of 4.482 J / cm 2 .
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated 6 to 7 times under the same condition.
- asterisk (**) indicates that p is less than 1%
- asterisk (***) indicates that p is less than 0.1%.
- the measured skin thickness after UV-B irradiation was 0.81 mm in the UV-B non-irradiated and D-methionine non-administered group (UV ( ⁇ ) / H 2 0), UV-B irradiated and D-methionine non-administered It was 1.25 mm in the group (UV (+) / H 2 0) and 1.00 in the group administered with UV-B irradiation and D-methionine (UV (+) / D-Met). From the above results, it was shown that the skin was significantly thickened by UV damage caused by UV-B irradiation, but D-methionine statistically significantly reduced this skin thickening.
- FIG. 4 shows the results of an experiment examining the effect of D-methionine on wrinkles generated by UV-B irradiation with a total irradiation dose of 4.482 J / cm 2 .
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated 6 to 7 times under the same condition.
- An asterisk (*) indicates that p is 1.8% in the Mann-Whitney U test.
- the number of individuals in each score after UV-B irradiation was 6 in the UV-B non-irradiated group and the D-methionine non-administered group (UV ( ⁇ ) control).
- UV (+) control The number of individuals in each of the UV-B-irradiated and D-methionine non-administered groups was 2 for score 4, 2 for score 5, 1 for score 6 and 1 for score 7 there were.
- the number of individuals in each of the UV-B irradiation and D-methionine administration groups (UV (+) D-Met) was 4 for rating 3, 2 for rating 4, and 1 for rating 5. From the above results, it was shown that wrinkle formation is remarkably increased by UV damage caused by UV-B irradiation, but D-methionine statistically significantly reduces this wrinkle formation.
- FIG. 5 shows the results of an experiment in which the effect of L- and D-methionine on wrinkles generated by UV-B irradiation in an amount according to Example 2 was examined.
- the error bar for each experimental condition indicates the standard deviation of the measured value of the experimental result repeated 6 to 8 times under the same condition.
- An asterisk (*) indicates that p is 0.55% in the Mann-Whitney U test.
- UV-B irradiation The number of individuals for each score after UV-B irradiation was 6 in the UV-B non-irradiated and D-methionine non-administered group (UV ( ⁇ ) control).
- the number of individuals in each of the UV-B-irradiated and D-methionine non-administered groups (UV (+) control) was 1 for score 5, 2 for score 6, 2 for score 7, and 3 for score 8. there were.
- the number of individuals in each of the UV-B irradiation and D-methionine administration groups (UV (+) D-Met) was 6 for score 5 and 2 for score 6.
- UV (+) L-Met The number of individuals in each of the UV-B irradiation and L-methionine administration groups (UV (+) L-Met) is 1 for score 4, 2 for score 5, 2 for score 6, and 2 for score 7. Met. From the above results, it was shown that wrinkle formation is remarkably increased by UV damage caused by UV-B irradiation, but D-methionine statistically significantly reduces this wrinkle formation. It was also shown that L-methionine reduces cell death by UV-A irradiation as shown in Example 1, but does not reduce wrinkle formation by UV-B irradiation as much as D-methionine.
- methionine containing methionine, tablets, soft capsules, granules, drinks, candy, cookies, miso, French dressing, mayonnaise, French bread, soy sauce, sprinkles, yogurt, seasoning / natto sauce, natto and moromi black vinegar
- Methionine in the following formulation examples is D-form and / or L-form. These formulation examples are listed for the purpose of illustration and are not intended to limit the technical scope of the present invention.
- Formulation Example 1 (tablet) (Composition) Formulation amount (mg / tablet) Methionine 360.5 Lactose 102.4 Carboxymethylcellulose calcium 29.9 Hydroxypropylcellulose 6.8 Magnesium stearate 5.2 Crystalline cellulose 10.2 515.0
- Formulation Example 2 (tablet) (Composition) Formulation amount (mg / tablet) Sucrose ester 70 Crystalline cellulose 74 Methylcellulose 36 Glycerin 25 Methionine 475 N-acetylglucosamine 200 Hyaluronic acid 150 Vitamin E 30 Vitamin B6 20 Vitamin B2 10 ⁇ -Lipoic acid 20 Coenzyme Q10 40 Ceramide (konjac extract) 50 L-proline 300 1500
- Formulation Example 3 (soft capsule) (Composition) Blending amount (mg / 1 capsule) Edible soybean oil 530 Eucommia extract 50 Carrot extract 50 Methionine 100 Royal Jelly 50 Maca 30 GABA 30 Beeslow 60 Gelatin 375 Glycerin 120 Glycerin fatty acid ester 105 1500
- Formulation Example 4 (soft capsule) (Composition) Blending amount (mg / 1 capsule) Brown rice germ oil 659 Methionine 500 Resveratrol 1 Lotus germ extract 100 Elastin 180 DNA 30 Folic acid 30 1500
- Formulation Example 5 (granule) (Composition) Blending amount (mg / pack) Methionine 400 Vitamin C 100 Soy isoflavone 250 Reduced lactose 300 Soybean oligosaccharide 36 Erythritol 36 Dextrin 30 Fragrance 24 Citric acid 24 1200
- Formulation Example 6 (Drink) (Composition) Compounding amount (in g / 60 mL) Eucommia extract 1.6 Carrot extract 1.6 Methionine 1.6 Reduced maltose starch syrup 28 Erythritol 8 Citric acid 2 Fragrance 1.3 N-acetylglucosamine 1 Hyaluronic acid Na 0.5 Vitamin E 0.3 Vitamin B6 0.2 Vitamin B2 0.1 ⁇ -Lipoic acid 0.2 Coenzyme Q10 1.2 Ceramide (konjac extract) 0.4 L-proline 2 Purified water residue 60
- Formulation Example 8 (Cookie) (Composition) Compounding amount (% by weight) Soft flour 45.0 Butter 17.5 Granulated sugar 20.0 Methionine 4.0 Egg 12.5 Fragrance 1.0 100.0
- rice bran that produces a large amount of methionine may be used.
- the rice bran can be selected by quantifying methionine by the method described in JP-A-2008-185558. Further, methionine or a salt thereof may be added to commercially available miso.
- Formulation Example 10 (French dressing) (Composition) Blending amount (g) Salad oil 27.0 Vinegar 30.0 Sodium chloride 0.9 Methionine 1.1 Pepper 1.0 60.0
- Formulation Example 11 (mayonnaise) (Composition) Blending amount (g) Salad oil 134.0 Vinegar 5 Sodium chloride 0.9 Methionine 1 Yolk 18 Sugar 0.2 Pepper 0.9 160.0
- Formulation Example 12 (French bread) (Composition) Blending amount (g) Powerful powder 140 Soft flour 60 Sodium chloride 3 Sugar 6 Methionine 2 Dry yeast 4 Lukewarm water 128 343
- Production method of Formulation Example 12 (French bread) Pre-fermented with 1 g of sugar and dry yeast in lukewarm water. Put flour, soft flour, sodium chloride, 5 g sugar and methionine in a bowl and put the pre-fermented yeast in it. After kneading sufficiently, it is made into a sphere and subjected to primary fermentation at 30 ° C. The dough is kneaded again, rested, shaped into a suitable shape, and finally fermented using an electronic fermenter. Bake in a 220 ° C oven for 30 minutes.
- soy sauce Add methionine to commercially available soy sauce and stir well. Further, instead of adding methionine or a salt thereof, soy sauce may be brewed using koji that produces a large amount of methionine. In order to obtain the rice bran, the rice bran can be selected by quantifying methionine by the method described in JP-A-2008-185558. Moreover, you may add methionine or its salt to commercially available soy sauce.
- Formulation Example 14 (yogurt) (Composition) Blending amount (g) Milk 880 L. Bulgaricus 50 S. Thermophilus 50 Methionine 20 1000
- Production method of Formulation Example 14 Fermentation is performed at 40 ° C to 45 ° C.
- Other commercially available inoculum may be used, and methionine may be added to commercially available yogurt.
- it can be selected by quantifying methionine by the method described in JP-A-2008-185558. Further, methionine or a salt thereof may be added to commercially available yogurt.
- Formulation Example 15 (sprinkle) (Composition) Blending amount (g) Methionine 50 Paste 15 L-glutamic acid Na 10 Sodium chloride 2 Roasted sesame 10 Crusher Clause 10 Sugar 1 Soy sauce 2 100
- Formulation Example 16 (Seasoning and natto sauce) (Composition) Blending amount (g) Commercial natto sauce 9 Methionine 1 10
- natto may be made using a bacterium that produces a large amount of methionine. In order to obtain the bacterium, it can be selected by quantifying methionine by the method described in JP-A-2008-185558. Further, methionine or a salt thereof may be added to commercially available natto.
- Formulation Example 18 (Moromi black vinegar) (Composition) Blending amount (g) Commercially available moromi black vinegar 900 Methionine 100 1000
- vinegar, black vinegar, or moromi may be made using a bacterium that produces a large amount of methionine. In order to obtain the bacterium, it can be selected by quantifying methionine by the method described in JP-A-2008-185558. Further, methionine or a salt thereof may be added to commercially available moromi black vinegar.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
紫外線照射及びメチオニン添加の方法
細胞は、市販のヒト新生児真皮線維芽細胞(Cryo NHDF-Neo、三光純薬)が用いられた。前記細胞は2x105個/mLとなるように市販の35mm径の培養ディッシュ(BD FALCON 353001、日本ベクトン・ディッキンソン)に播種され、市販の細胞培養用培地(D-MEM(1g/Lグルコース)、和光純薬)に牛胎児血清を10%、抗生物質(15240-062、GIBCO)を1%添加した培地(以下、「通常培地」という。)を用いて培養された。前記細胞は、37°C、5%CO2及び飽和水蒸気雰囲気下で約24時間培養された。
紫外線照射前のメチオニン添加(以下、「照射前添加」という。)の効果を検討する場合には、照射24時間前に0.001ないし100μMのL-又はD-メチオニンを添加したBSO培地に切り換えた。0.1μMのD-プロリンを添加した培地に切り換えた後の紫外線照射を陽性対照とし、これらのアミノ酸を添加しない培地のままでの紫外線照射を陰性対照とした。
塩化鉄(II)を蒸留水に2×10-3%となるように溶解し、その溶解液を200倍希釈(終濃度1×10-5%)となるようにカルシウムイオン、マグネシウムイオンを含んだリン酸緩衝生理食塩水PBS(+)で希釈して作製した培地(以下、「紫外線照射用培地」という。)を37°Cに予め加温して用いた。
UV-A照射前に培地は前記紫外線照射用培地1mLに置換された。UV-A照射は紫外光均一露光装置UVE-502S+EL-160(三永電機製作所)を用いて、培養ディッシュの蓋を除去した状態で該培養ディッシュのおよそ20cm上部から320nmないし400nmの紫外線を8又は9J/cm2照射して実施された。紫外線量はUV RADIOMETER UVR-3036/S(株式会社トプコン)を用いて測定された。
紫外線照射後、前記通常培地に戻して40時間、37°C、5%CO2及び飽和水蒸気雰囲気下で培養された。紫外線照射後のメチオニン添加(以下、「照射後添加」という。)の効果を検討する場合には、この40時間の培養の培地に0.001ないし100μMのL-又はD-メチオニンを添加した。
その後、培地にalamarBlue(商標、Invitrogen)を最終濃度10%となるように添加し、3時間後に、Ahmed S.A.ら、(J. Immunol. Method. 170,211-224(1994))及び製造者の指示書に従って励起波長544nm、蛍光波長590nmで上清の蛍光強度を測定した。
図1にUV―A 9J/cm2の紫外線照射による線維芽細胞の障害に対するL-又はD-メチオニンの照射前添加の効果を調べた実験結果を示す。各実験条件の誤差棒は同一条件で4回繰り返した実験結果の測定値の標準偏差を示す。また、Bonferroni/Dunn検定において、アステリスク(*)はpが5%未満、アステリスク(**)はpが1%未満、アステリスク(***)はpが0.1%未満であることを示す。
図2にUV―A 8J/cm2の紫外線照射による線維芽細胞の障害に対するD-メチオニンの照射後添加の効果を調べた実験結果を示す。各実験条件の誤差棒は同一条件で4回繰り返した実験結果の測定値の標準偏差を示す。また、アステリスク(***)はBonferroni/Dunn検定でpが0.1%未満であることを示す。
紫外線照射及びD-メチオニン投与の方法
雄性ヘアレスマウス(Hos:HR-1、6週齢、星野実験動物)を用い、シュワルツらの方法(Haratake A.et al.J.Invest.Dermatol.108:769-775,1997.)を一部変更して、UV-Bを繰り返し照射する方法(Naganuma M.et al.J.Dermatol.Sci.25:29-35,2001.Schwartz E.J.Invest.Dermatol.91:158-161,1988.)に準じてシワを形成させた。すなわち背部にUV-B(光源;東芝エレクトリック製 東芝 FL-20 SE蛍光ランプ)を週3回、12週間照射した。開始後の照射量は36mJ/cm2/回とし、2週目以降は徐々に増加させ、12週目は216mJ/cm2/回とした。総照射量は4.482J/cm2であった。紫外線量はUVRADIOMETER(UVR-305/365D(II)、トプコン)にて測定した値を用いた。また、UV-B照射期間中、10mMのD-メチオニンが給水瓶にて投与された。対照として、飲料水が同様の方法にて投与された。給水瓶は1週間に1度交換された。
紫外線照射の終了後に、皮膚厚をシックネスゲージ(Mitsutoyo Corporation、PK-1012SU)を用いて測定した。皮膚厚の測定値は、シックネスゲージで皮膚を挟み込んで測定したため、「皮膚厚×2」として記載した。
マウスへの上記紫外線照射終了後に、マウス背部の写真を撮影し、ビセットらの方法(Bissett DL.et al.Photochemistry and Photobiology 46:367-378,1987.)を一部変えた方法でシワの生成の度合いを下記の表1に示す判定基準に従って評価した。シワの評価作業は4名の測定者が個別に行い、その後合議によって、シワの生成の度合いについての評点(以下、単に「評点」という。)を決定した。
図3に総照射量4.482J/cm2のUV-B照射によって生じる皮膚の肥厚に対するD-メチオニンの効果を調べた実験の結果を示す。各実験条件の誤差棒は同一条件で6ないし7回繰り返した実験結果の測定値の標準偏差を示す。また、Bonferroni/Dunn検定において、アステリスク(**)はpが1%未満、アステリスク(***)はpが0.1%未満であることを示す。UV-B照射後の皮膚厚の測定値は、UV-B非照射かつD-メチオニン非投与群(UV(-)/H20)で0.81mm、UV-B照射かつD-メチオニン非投与群(UV(+)/H20)で1.25mm及びUV-B照射かつD-メチオニン投与群(UV(+)/D-Met)で1.00であった。以上の結果から、UV-B照射による紫外線障害によって皮膚は顕著に肥厚するが、D-メチオニンはこの皮膚の肥厚を統計的に有意に軽減することが示された。
図4に総照射量4.482J/cm2のUV-B照射によって生じるシワに対するD-メチオニンの効果を調べた実験の結果を示す。各実験条件の誤差棒は同一条件で6ないし7回繰り返した実験結果の測定値の標準偏差を示す。また、アステリスク(*)はMann-WhitneyのU検定でpが1.8%であることを示す。UV-B照射後の各評点の個体数は、UV-B非照射かつD-メチオニン非投与群(UV(-)control)では評点1が6匹であった。UV-B照射かつD-メチオニン非投与群(UV(+)control)の各評点の個体数は、評点4が2匹、評点5が2匹、評点6が1匹及び評点7が1匹であった。UV-B照射かつD-メチオニン投与群(UV(+)D-Met)の各評点の個体数は、評点3が4匹、評点4が2匹及び評点5が1匹であった。以上の結果から、UV-B照射による紫外線障害によってシワ形成は顕著に増大するが、D-メチオニンはこのシワ形成を統計的に有意に軽減することが示された。
方法
UV-B照射期間中、10mMのL-又はD-メチオニンが給水瓶にて投与された。紫外線照射及びシワ生成の判定は、実施例2で説明された方法で行なわれた。
図5に実施例2に準じる量のUV-B照射によって生じるシワに対するL-及びD-メチオニンの効果を調べた実験の結果を示す。各実験条件の誤差棒は同一条件で6ないし8回繰り返した実験結果の測定値の標準偏差を示す。また、アステリスク(*)はMann-WhitneyのU検定でpが0.55%であることを示す。
(組成物) 配合量(mg/1錠中)
メチオニン 360.5
乳糖 102.4
カルボキシメチルセルロースカルシウム 29.9
ヒドロキシプロピルセルロース 6.8
ステアリン酸マグネシウム 5.2
結晶セルロース 10.2
515.0
(組成物) 配合量(mg/1錠中)
ショ糖エステル 70
結晶セルロース 74
メチルセルロース 36
グリセリン 25
メチオニン 475
N-アセチルグルコサミン 200
ヒアルロン酸 150
ビタミンE 30
ビタミンB6 20
ビタミンB2 10
α-リポ酸 20
コエンザイムQ10 40
セラミド(コンニャク抽出物) 50
L-プロリン 300
1500
(組成物) 配合量(mg/1カプセル中)
食用大豆油 530
トチュウエキス 50
ニンジンエキス 50
メチオニン 100
ローヤルゼリー 50
マカ 30
GABA 30
ミツロウ 60
ゼラチン 375
グリセリン 120
グリセリン脂肪酸エステル 105
1500
(組成物) 配合量(mg/1カプセル中)
玄米胚芽油 659
メチオニン 500
レスベラトロール 1
ハス胚芽エキス 100
エラスチン 180
DNA 30
葉酸 30
1500
(組成物) 配合量(mg/1包中)
メチオニン 400
ビタミンC 100
大豆イソフラボン 250
還元乳糖 300
大豆オリゴ糖 36
エリスリトール 36
デキストリン 30
香料 24
クエン酸 24
1200
(組成物) 配合量(g/60mL中)
トチュウエキス 1.6
ニンジンエキス 1.6
メチオニン 1.6
還元麦芽糖水飴 28
エリスリトール 8
クエン酸 2
香料 1.3
N-アセチルグルコサミン 1
ヒアルロン酸Na 0.5
ビタミンE 0.3
ビタミンB6 0.2
ビタミンB2 0.1
α-リポ酸 0.2
コエンザイムQ10 1.2
セラミド(コンニャク抽出物) 0.4
L-プロリン 2
精製水 残余
60
(組成物) 配合量(重量%)
砂糖 50
水飴 48
メチオニン 1
香料 1
100
(組成物) 配合量(重量%)
薄力粉 45.0
バター 17.5
グラニュー糖 20.0
メチオニン 4.0
卵 12.5
香料 1.0
100.0
バターを撹拌しながらグラニュー糖を徐々に添加し、卵、メチオニン及び香料を添加して撹拌した。十分に混合した後、均一に振るった薄力粉を加えて低速で撹拌し、塊状で冷蔵庫で寝かせた。その後、成型し170°C15分間焼成しクッキーとした。
(組成物) 配合量(g)
大豆 1000
米麹 1000
塩 420
メチオニン 158
水 残余
4000
米こうじと塩とをよく混ぜ合わせる。洗浄した大豆を3倍量の水に一晩つけた後に水を切り、新しい水を加えながら煮込み、ざるにあける。煮汁(種水)を集め、メチオニンを10%w/vとなるように溶解する。煮あがった豆を直ちにすりつぶし、塩を混ぜた米麹を加えて、上記のメチオニンを溶解した種水を足しながら粘土程の固さになるまでむらなく混ぜ合わせる。団子状に丸めたものを桶に隙間のない様に隅々まで、しっかりと詰め込み、表面を平らにしてラップで覆い密封する。3箇月後に容器を移し変え、表面を平らにしてラップで覆う。なお、メチオニンを種水に加える代わりに、メチオニンを多く産生する米麹を用いてもよい。前記米麹を得るには、特開2008-185558に記載の方法でメチオニンを定量することにより選抜することができる。また、市販の味噌にメチオニンまたはその塩を加えてもよい。
(組成物) 配合量(g)
サラダ油 27.0
酢 30.0
塩化ナトリウム 0.9
メチオニン 1.1
胡椒 1.0
60.0
酢に塩化ナトリウム及びメチオニンを加えた後に、よく攪拌して溶解する。サラダ油を加えて、よく攪拌し胡椒を加える。
(組成物) 配合量(g)
サラダ油 134.0
酢 5
塩化ナトリウム 0.9
メチオニン 1
卵黄 18
砂糖 0.2
胡椒 0.9
160.0
卵黄(室温)に酢、塩化ナトリウム、メチオニン及び胡椒を加えて、泡立て器で十分に攪拌する。サラダ油を少しずつ加えながら攪拌を継続してエマルジョンにする。最後に砂糖を加えて攪拌する。
(組成物) 配合量(g)
強力粉 140
薄力粉 60
塩化ナトリウム 3
砂糖 6
メチオニン 2
ドライイースト 4
ぬるま湯 128
343
ぬるま湯に砂糖1g及びドライイーストを入れて予備発酵させる。強力粉、薄力粉、塩化ナトリウム、砂糖5g及びメチオニンをボウルに入れ、その中に予備発酵させたイーストを入れる。十分捏ねた後に球状にして30°Cで一次発酵させる。生地を再度捏ねてから休ませた後に適当な形に整形して電子発酵機を用いて最終発酵させる。クープを入れて220°Cのオーブンで30分間焼く。
(組成物) 配合量(g)
市販の醤油 980
メチオニン 20
1000
市販の醤油にメチオニンを加えてよく攪拌する。また、メチオニンやその塩を加える代わりに、メチオニンを多く産生する麹を用いて醤油を醸造してもよい。前記米麹を得るには、特開2008-185558に記載の方法でメチオニンを定量することにより選抜することができる。また、市販の醤油にメチオニンまたはその塩を加えてもよい。
(組成物) 配合量(g)
牛乳 880
L.ブルガリカス菌 50
S.サーモフィルス菌 50
メチオニン 20
1000
40°C~45°Cで発酵させる。他の市販の種菌を用いてもよく、市販のヨーグルトにメチオニンを加えてもよい。また、メチオニンやその塩を加える代わりに、メチオニンを多く産生する菌を用いてもよい。前記菌を得るには、特開2008-185558に記載の方法でメチオニンを定量することにより選抜することができる。また、市販のヨーグルトにメチオニンまたはその塩を加えてもよい。
(組成物) 配合量(g)
メチオニン 50
のり 15
L-グルタミン酸Na 10
塩化ナトリウム 2
煎りごま 10
さば削り節 10
砂糖 1
醤油 2
100
(組成物) 配合量(g)
市販の納豆のたれ 9
メチオニン 1
10
(組成物) 配合量(g)
市販の納豆 19.9
メチオニン 0.1
20
メチオニン又はその塩を加える代わりに、メチオニンを多く産生する菌を用いて納豆を作ってもよい。前記菌を得るには、特開2008-185558に記載の方法でメチオニンを定量することにより選抜することができる。また、市販の納豆にメチオニンまたはその塩を加えてもよい。
(組成物) 配合量(g)
市販のもろみ黒酢 900
メチオニン 100
1000
メチオニン又はその塩を加える代わりに、メチオニンを多く産生する菌を用いて酢、黒酢、もろみを作ってもよい。前記菌を得るには、特開2008-185558に記載の方法でメチオニンを定量することにより選抜することができる。また、市販のもろみ黒酢にメチオニンまたはその塩を加えてもよい。
Claims (10)
- メチオニンと、その誘導体及び/又は塩とからなる群から選択される1種類又は2種類以上の化合物を含むことを特徴とする、紫外線障害軽減経口組成物。
- 前記メチオニンはD-体であることを特徴とする、請求項1に記載の組成物。
- シワ抑制剤であることを特徴とする、請求項1又は2に記載の組成物。
- 皮膚疾患用医薬品として用いられることを特徴とする、請求項1ないし3のいずれか1つに記載の組成物。
- 前記皮膚疾患は、紅斑、日光皮膚炎、慢性光線皮膚症、光線角化症、光線口唇炎、Favre-Racouchot病、光線過敏症、光接触皮膚炎、ベルロック皮膚炎、光線過敏性薬疹、多形日光疹、種痘様水泡症、日光蕁麻疹、慢性光線過敏性皮膚炎、色素性乾皮症、雀卵斑、ポルフィリン症、ペラグラ、Hartnup病、日光角化症、皮膚筋炎、扁平苔癬、Darier病、毛孔性紅色粃糠疹、酒さ、アトピー性皮膚炎、肝斑、単純性疱疹、エリテマトーデス、扁平上皮癌、基底細胞癌及びBowen病からなるグループから選択されることを特徴とする、請求項4に記載の組成物。
- 前記皮膚疾患用医薬品は皮膚疾患用治療剤であることを特徴とする、請求項4又は5に記載の組成物。
- 前記皮膚疾患用医薬品は皮膚疾患用予防剤であることを特徴とする、請求項4又は5に記載の組成物。
- 食品として用いられることを特徴とする、請求項1又は2に記載の組成物。
- 白内障用医薬品として用いられることを特徴とする、請求項1又は2に記載の組成物。
- 前記白内障用医薬品は白内障用治療剤又は白内障用予防剤であることを特徴とする、請求項9に記載の組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/261,161 US20120189563A1 (en) | 2009-09-30 | 2010-03-31 | Oral composition for alleviating ultraviolet irradiation-induced damage |
JP2011534100A JP5703228B2 (ja) | 2009-09-30 | 2010-03-31 | 紫外線障害軽減経口組成物 |
TW099110035A TW201110995A (en) | 2009-09-30 | 2010-03-31 | Oral composition for alleviation of ultraviolet radiation-induced damage |
EP10820190.6A EP2484353A4 (en) | 2009-09-30 | 2010-03-31 | ORAL ACCEPTABLE COMPOSITION FOR TREATMENT BY ULTRAVIOLETTREADING OF INDIRECT DAMAGES |
CN2010800366376A CN102481277A (zh) | 2009-09-30 | 2010-03-31 | 紫外线损伤减轻口服组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009228267 | 2009-09-30 | ||
JP2009-228267 | 2009-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011040070A1 true WO2011040070A1 (ja) | 2011-04-07 |
Family
ID=43825907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/055841 WO2011040070A1 (ja) | 2009-09-30 | 2010-03-31 | 紫外線障害軽減経口組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120189563A1 (ja) |
EP (1) | EP2484353A4 (ja) |
JP (1) | JP5703228B2 (ja) |
KR (1) | KR20120044993A (ja) |
CN (1) | CN102481277A (ja) |
TW (1) | TW201110995A (ja) |
WO (1) | WO2011040070A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043185A1 (ja) * | 2010-09-30 | 2012-04-05 | 株式会社資生堂 | Il-8発現抑制組成物 |
JP2013177356A (ja) * | 2012-02-29 | 2013-09-09 | Shiseido Co Ltd | 紫外線曝露によって促進される血管新生を抑制するための組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2677618T3 (es) * | 2009-09-14 | 2018-08-03 | Shiseido Company, Ltd. | Composición para mitigar daños inducidos por radiación ultravioleta |
CN103520397B (zh) * | 2013-10-31 | 2015-04-15 | 刘青云 | 一种治疗毛发红糠疹的中药 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05320036A (ja) * | 1992-05-19 | 1993-12-03 | Shiseido Co Ltd | 一重項酸素除去組成物 |
JPH08225428A (ja) * | 1995-02-23 | 1996-09-03 | Kao Corp | 化粧料 |
JPH10279543A (ja) * | 1997-04-03 | 1998-10-20 | Ajinomoto Co Inc | アミノ酸誘導体及び抗活性酸素剤 |
JPH11246396A (ja) * | 1998-02-27 | 1999-09-14 | Shiseido Co Ltd | 免疫賦活剤 |
JP2005003558A (ja) | 2003-06-12 | 2005-01-06 | Shiseido Co Ltd | 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法 |
JP2007525201A (ja) * | 2003-07-07 | 2007-09-06 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | コンパニオンアニマルにおいて改良された酸化的状態を得るための組成物 |
JP2007284435A (ja) * | 2006-03-22 | 2007-11-01 | Shiono Koryo Kk | 新規化合物、抗酸化剤及び化粧料、飲食品 |
JP2008513455A (ja) * | 2004-09-14 | 2008-05-01 | モレキュラー セラピューティクス インコーポレーティッド | 改良された生物薬剤学的性質をもつd−メチオニン製剤 |
JP2008185558A (ja) | 2007-01-31 | 2008-08-14 | Shiseido Co Ltd | 2次元液体クロマトグラフィー分析方法および分取用流路切り替えユニット |
JP2009532480A (ja) * | 2006-04-04 | 2009-09-10 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の抗酸化的な状態を増強する組成物および方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
DK0951842T3 (da) * | 1999-01-20 | 2003-01-06 | Nutricia Nv | Ernæringsprodukt til et spædbarn |
JP4520089B2 (ja) * | 2002-05-31 | 2010-08-04 | サントリーホールディングス株式会社 | ルブロフサリン配糖体含有組成物 |
US20050090551A1 (en) * | 2003-10-27 | 2005-04-28 | Board Of Trustees Of Southern Illinois University | Therapeutic use of methionine for the treatment or prevention of mucositis |
ES2677618T3 (es) * | 2009-09-14 | 2018-08-03 | Shiseido Company, Ltd. | Composición para mitigar daños inducidos por radiación ultravioleta |
JP2012077022A (ja) * | 2010-09-30 | 2012-04-19 | Shiseido Co Ltd | Il−8発現抑制組成物 |
-
2010
- 2010-03-31 TW TW099110035A patent/TW201110995A/zh unknown
- 2010-03-31 JP JP2011534100A patent/JP5703228B2/ja active Active
- 2010-03-31 US US13/261,161 patent/US20120189563A1/en not_active Abandoned
- 2010-03-31 EP EP10820190.6A patent/EP2484353A4/en not_active Withdrawn
- 2010-03-31 CN CN2010800366376A patent/CN102481277A/zh active Pending
- 2010-03-31 WO PCT/JP2010/055841 patent/WO2011040070A1/ja active Application Filing
- 2010-03-31 KR KR1020127002368A patent/KR20120044993A/ko not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05320036A (ja) * | 1992-05-19 | 1993-12-03 | Shiseido Co Ltd | 一重項酸素除去組成物 |
JPH08225428A (ja) * | 1995-02-23 | 1996-09-03 | Kao Corp | 化粧料 |
JPH10279543A (ja) * | 1997-04-03 | 1998-10-20 | Ajinomoto Co Inc | アミノ酸誘導体及び抗活性酸素剤 |
JPH11246396A (ja) * | 1998-02-27 | 1999-09-14 | Shiseido Co Ltd | 免疫賦活剤 |
JP2005003558A (ja) | 2003-06-12 | 2005-01-06 | Shiseido Co Ltd | 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法 |
JP2007525201A (ja) * | 2003-07-07 | 2007-09-06 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | コンパニオンアニマルにおいて改良された酸化的状態を得るための組成物 |
JP2008513455A (ja) * | 2004-09-14 | 2008-05-01 | モレキュラー セラピューティクス インコーポレーティッド | 改良された生物薬剤学的性質をもつd−メチオニン製剤 |
JP2007284435A (ja) * | 2006-03-22 | 2007-11-01 | Shiono Koryo Kk | 新規化合物、抗酸化剤及び化粧料、飲食品 |
JP2009532480A (ja) * | 2006-04-04 | 2009-09-10 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の抗酸化的な状態を増強する組成物および方法 |
JP2008185558A (ja) | 2007-01-31 | 2008-08-14 | Shiseido Co Ltd | 2次元液体クロマトグラフィー分析方法および分取用流路切り替えユニット |
Non-Patent Citations (15)
Title |
---|
"Harper's Biochemistry", 1991, MARUZEN CO., LTD., pages: 21 - 30 |
"HIFUSHIKKAN SAISHIN NO CHIRYO", 2005, NANKODO CO., LTD |
"HYOJUN HIFUKAGAKU", IGAKU-SHOIN LTD |
AHMED S.A. ET AL., J. IMMUNOL. METHOD., vol. 170, 1994, pages 211 - 224 |
BISSETT DL. ET AL., PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 46, 1987, pages 367 - 378 |
FUJINAGA, Y. ET AL.: "HAKUNAISHO GANKA", 1982, KANEHARA & CO., LTD., pages: 10 |
HARATAKE A. ET AL., J. INVEST. DERMATOL., vol. 108, 1997, pages 769 - 775 |
KINOUCHI, T. ET AL., TANPAKUSHITSU KAKUSAN KOSO (PROTEIN, NUCLEIC ACID AND ENZYME, vol. 50, 2005, pages 453 - 460 |
LEHNINGER: "Principles of Biochemistry", vol. 1, 1993, HIROKAWA PUBLISHING CO., pages: 132 - 147 |
MAEDA, T.; IWATA, S.: "SUISHOTAI SONO SEIKAGAKUTEKI KIKO", 1986, MEDICAL-AOI PUBLISHINGS, INC., pages: 318 - 323 |
MORIKAWA, A. ET AL., AMINO ACIDS, vol. 32, 2007, pages 13 - 20 |
NAGANUMA M. ET AL., J. DERMATOL. SCI., vol. 25, 2001, pages 29 - 35 |
SCHWARTZ E., J. INVEST. DERMATOL., vol. 91, 1988, pages 158 - 161 |
See also references of EP2484353A4 |
ZIGMAN, S. ET AL., INVEST. OPHTHALMOL. VISUAL SCI., vol. 18, 1979, pages 462 - 467 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043185A1 (ja) * | 2010-09-30 | 2012-04-05 | 株式会社資生堂 | Il-8発現抑制組成物 |
JP2013177356A (ja) * | 2012-02-29 | 2013-09-09 | Shiseido Co Ltd | 紫外線曝露によって促進される血管新生を抑制するための組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2484353A4 (en) | 2013-04-17 |
KR20120044993A (ko) | 2012-05-08 |
JPWO2011040070A1 (ja) | 2013-02-21 |
CN102481277A (zh) | 2012-05-30 |
EP2484353A1 (en) | 2012-08-08 |
TW201110995A (en) | 2011-04-01 |
JP5703228B2 (ja) | 2015-04-15 |
US20120189563A1 (en) | 2012-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5934405B2 (ja) | 紫外線障害軽減組成物 | |
JP5795960B2 (ja) | 紫外線障害軽減組成物 | |
WO2011040363A1 (ja) | コラーゲン産生促進組成物 | |
JP5703228B2 (ja) | 紫外線障害軽減経口組成物 | |
JP6018752B2 (ja) | 抗酸化組成物 | |
WO2012043185A1 (ja) | Il-8発現抑制組成物 | |
WO2011040185A1 (ja) | 肌あれ軽減経口組成物 | |
WO2011040166A1 (ja) | シワ形成軽減経口組成物 | |
WO2013128736A1 (ja) | 紫外線曝露によって促進される血管新生を抑制するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080036637.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10820190 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011534100 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010820190 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127002368 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201000636 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13261161 Country of ref document: US |